Clinical relevance of HCV antiviral drug resistance

Current Opinion in Virology

Volumn 2, Issue 5, 2012, Pages 651-655

  Welsch, C ^a   Zeuzem, S ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; DANOPREVIR; PEGINTERFERON; RIBAVIRIN; TELAPREVIR;

ANTIVIRAL RESISTANCE; ARTICLE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; PRIORITY JOURNAL; TREATMENT FAILURE;

EID: 84867399275     PISSN: 18796257     EISSN: 18796265     Source Type: Journal    
DOI: 10.1016/j.coviro.2012.08.008     Document Type: Review

References (25)

1. VICTRELIS™ (boceprevir) Full prescribing information (www.victrelis.com, revised 5/2011).
2. INCIVEK™ (telaprevir) Full prescribing information (www.incivek.com, revised 5/2011).
3. C. Welsch, A.B. Jesudian, S. Zeuzem, and I.M. Jacobson New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives Gut 61 Suppl. 1 2012 i36 i46
4. T. Shimakami, C. Welsch, D. Yamane, D. McGivern, M. Yi, S. Zeuzem, and S.M. Lemon Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus Gastroenterology 140 2011 667 675
5. C. Welsch, T. Shimakami, C. Hartmann, Y. Yang, F.S. Domingues, T. Lengauer, S. Zeuzem, and S.M. Lemon Peptidomimetic escape arise due to genetic diversity in the ligand-binding site of the HCV NS3/4A serine protease Gastroenterology 142 2012 654 663
6. L. Rong, H. Dahari, R.M. Ribeiro, and A.S. Perelson Rapid emergence of protease inhibitor resistance in hepatitis C virus Sci Transl Med 2 2010 30ra32
7. S. Susser, C. Welsch, Y. Wang, M. Zettler, F.S. Domingues, U. Karey, E. Hughes, R. Ralston, X. Tong, E. Herrmann, and S. Zeuzem Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients Hepatology 50 2009 1709 1718
8. C. Sarrazin, T.L. Kieffer, D. Bartels, B. Hanzelka, U. Muh, M. Welker, D. Wincheringer, Y. Zhou, H.M. Chu, C. Lin, and C. Weegink Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir Gastroenterology 132 2007 1767 1777
9. T. Kuntzen, J. Timm, A. Berical, N. Lennon, A.M. Berlin, S.K. Young, B. Lee, D. Heckerman, J. Carlson, L.L. Reyor, and M. Kleyman Naturally occuring dominant resistance mutations to the hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients Hepatology 48 2008 1769 1778
10. F. Poordad, J.J. McCone, B.R. Bacon, S. Bruno, M.P. Manns, M. Sulkowski, I.M. Jacobson, K.R. Reddy, Z.D. Goodman, N. Boparai, and M.J. DiNubile Boceprevir for untreated chronic HCV genotype 1 infection N Engl J Med 364 2011 1195 1206
11. B.R. Bacon, S.C. Gordon, E. Lawitz, P. Marcellin, J.M. Vierling, S. Zeuzem, F. Poordad, Z.D. Goodman, H.L. Sings, N. Boparai, and M. Burroughs Boceprevir for previously treated chronic HCV genotype 1 infection N Engl J Med 364 2011 1207 1217
12. C. Sarrazin, and S. Zeuzem Resistance to direct antiviral agents in patients with hepatitis C virus infection Gastroenterology 138 2010 447 462
13. M.H. Powdrill, E.P. Tchesnokov, R.A. Kozak, R.S. Russell, R. Martin, E.S. Svarovskaia, H. Mo, R.D. Kouyos, and M. Götte Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance Proc Natl Acad Sci U S A 108 2011 20509 20513
14. C. Hezode, N. Forestier, G. Dusheiko, P. Ferenci, S. Pol, T. Goeser, J.P. Bronowicki, M. Bourliere, S. Gharakhanian, L. Bengtsson, and L. McNair Telaprevir and peginterferon with or without ribavirin for chronic HCV infection N Engl J Med 360 2009 1839 1850
15. J.G. McHutchison, G.T. Everson, S.C. Gordon, I.M. Jacobson, M. Sulkowski, R. Kauffman, L. McNair, J. Alam, and A.J. Muir Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection N Engl J Med 360 2009 1827 1838
16. D. Ge, J. Fellay, A.J. Thompson, J.S. Simon, K.V. Shianna, T.J. Urban, E.L. Heinzen, P. Qiu, A.H. Bertelsen, A.J. Muir, and M. Sulkowski Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance Nature 461 2009 399 401
17. C. Welsch, and S. Zeuzem Will interferon-free regimens prevail? Gastroenterology 142 2012 1351 1355
18. S. Zeuzem, R.J. Barnard, J.A. Howe, R.A. Ogert, R. Ralston, N. Boparai, C.A. Brass, J.K. Albrecht, M. Burroughs, and V. Sniukiene Boceprevir resistance-associated variants (RAVS) are observed more frequently in HCV (GT1)-infected patients with poor response to peginterferon alfa-2b/ribavirin EASL Berlin 2011 (Abstract 9)
19. J.M. Vierling, R. Ralston, E.J. Lawitz, J. McCone, S. Gordon, D. Pound, M. Davis, J. Galati, I. Jacobson, and L. Rossaro Long-term outcomes following combinations treatment with boceprevir plus pegintron/ribavirin (P/R) in patients with chronic hepatitis C, genotype 1 (CHC-G1) EASL Vienna 2010 (Abstract 2016)
20. J.C. Sullivan, S. De Meyer, D.J. Bartels, I. Dierynck, E. Zhang, J. Spanks, A. Tigges, N. Adda, E.C. Martin, and I.M. Jacobson Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials EASL Berlin 2011 (Abstract 8)
21. K.E. Sherman, M.S. Sulkowski, F. Zoulim, A. Alberti, L.J. Wei, J.C. Sullivan, E.C. Martin, T.L. Kieffer, S. De Meyer, and G. Picchio Follow-up of SVR durability and viral resistance in patients with chronic hepatitis C treated with telaprevir-based regimens: interim analysis from the EXTEND study AASLD San Francisco 2011 (Abstract 248)
22. S. Susser, J. Vermehren, N. Forestier, M.W. Welker, N. Grigorian, C. Füller, D. Perner, S. Zeuzem, and C. Sarrazin Analysis of long-term persistance of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir J Clin Virol 52 2011 321 327
23. S. Susser, S.E. Schelhorn, D. Perner, N. Grigorian, T. Lengauer, S. Zeuzem, and C. Sarrazin Long-term follow-up analysis of the hepatitis C virus NS3 protease in patients treated with telaprevir or boceprevir: a comparison between clonal and deep sequencing AASLD San Francisco 2011 (Abstract 2104)
24. C. Sarrazin, H.W. Reesink, S. Zeuzem, C.J. Weegink, D. Luo, J. Witek, T.L. Kieffer, D. Bartels, I. Dierynck, S. De Meyer, and G. Picchio Retreatment with telaprevir/PEG-IFN/RBV after a short exposure to telaprevir in phase I studies: interim results from a phase IIIB rollover trial (C219) AASLD San Francisco 2011 (Abstract 35)
25. O. Lenz, J. de Bruijne, L. Vijgen, T. Verbinnen, C. Weegink, H. van Marck, I. Vandenbroucke, M. Peeters, G. De Smedt, and K. Simmen Treatment outcome and resistance analysis in HCV genotype 1 patients previously exposed to TMC435 monotherapy and re-treated with TMC435 in combination with PegIFNa-2a/ribavirin EASL 2011 (Abstract 2068)